[{"id":"14077522-c4f9-49b8-a790-5ed5d6ceade7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04928612","created_at":"2025-03-03T15:59:29.814Z","updated_at":"2025-03-03T15:59:29.814Z","phase":"Phase 1","brief_title":"A Study of CBP-1018 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04928612","lead_sponsor":"Coherent Biopharma (Suzhou) Co., Ltd.","biomarkers":" FOLR1","pipe":"","alterations":" ","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CBP-1018"],"overall_status":"Recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 11/04/2021","start_date":" 11/04/2021","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-08-28"},{"id":"63510f70-5f36-4b34-ad53-482142faa7dd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05397093","created_at":"2022-05-31T12:54:49.543Z","updated_at":"2024-07-02T16:35:16.459Z","phase":"Phase 1","brief_title":"ITIL-306 in Advanced Solid Tumors","source_id_and_acronym":"NCT05397093","lead_sponsor":"Instil Bio","biomarkers":" EGFR • KRAS • ALK • BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["EGFR • KRAS • ALK • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • ITIL-306"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 08/24/2022","start_date":" 08/24/2022","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 11/01/2039","study_completion_date":" 11/01/2039","last_update_posted":"2024-03-05"},{"id":"995d7ed3-58bc-4c2b-813c-b6a4de641715","acronym":"CRUKD14/001","url":"https://clinicaltrials.gov/study/NCT02546921","created_at":"2022-05-26T00:57:40.094Z","updated_at":"2024-07-02T16:35:46.536Z","phase":"Phase 1","brief_title":"Phase I Study of MOv18 IgE","source_id_and_acronym":"NCT02546921 - CRUKD14/001","lead_sponsor":"Cancer Research UK","biomarkers":" MUC16","pipe":" | ","alterations":" MUC16 elevation","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MOv18 IgE"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 02/16/2016","start_date":" 02/16/2016","primary_txt":" Primary completion: 06/22/2021","primary_completion_date":" 06/22/2021","study_txt":" Completion: 07/30/2021","study_completion_date":" 07/30/2021","last_update_posted":"2023-06-05"},{"id":"7dbbc938-f2df-43be-869e-296694ec3653","acronym":"","url":"https://clinicaltrials.gov/study/NCT02593227","created_at":"2021-01-18T12:35:08.510Z","updated_at":"2024-07-02T16:36:27.756Z","phase":"Phase 2","brief_title":"Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer","source_id_and_acronym":"NCT02593227","lead_sponsor":"Marker Therapeutics, Inc.","biomarkers":" HER-2 • FOLR1","pipe":" | ","alterations":" FOLR1 expression","tags":["HER-2 • FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • TPIV200 • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 80","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 07/15/2021","primary_completion_date":" 07/15/2021","study_txt":" Completion: 07/15/2021","study_completion_date":" 07/15/2021","last_update_posted":"2021-07-19"},{"id":"678dd935-0e9a-49cb-b971-1b8f045a84fd","acronym":"MORAb-003-009","url":"https://clinicaltrials.gov/study/NCT01218516","created_at":"2021-01-18T04:53:31.074Z","updated_at":"2024-07-02T16:36:41.838Z","phase":"Phase 2","brief_title":"A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung","source_id_and_acronym":"NCT01218516 - MORAb-003-009","lead_sponsor":"Morphotek","biomarkers":" FOLR1","pipe":"","alterations":" ","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • pemetrexed • farletuzumab (MORAB-003)"],"overall_status":"Completed","enrollment":" Enrollment 130","initiation":"Initiation: 06/27/2011","start_date":" 06/27/2011","primary_txt":" Primary completion: 12/15/2012","primary_completion_date":" 12/15/2012","study_txt":" Completion: 11/01/2013","study_completion_date":" 11/01/2013","last_update_posted":"2020-08-20"},{"id":"fe040a95-8a63-460a-9602-c2d63a78dd68","acronym":"MORAB-003-J081-102","url":"https://clinicaltrials.gov/study/NCT01049061","created_at":"2021-01-18T04:07:17.178Z","updated_at":"2024-07-02T16:36:44.265Z","phase":"Phase 1","brief_title":"A Study of MORAb-003 in Patients With Solid Tumor","source_id_and_acronym":"NCT01049061 - MORAB-003-J081-102","lead_sponsor":"Eisai Co., Ltd.","biomarkers":" FOLR1","pipe":" | ","alterations":" FOLR1 expression","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e farletuzumab (MORAB-003)"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 01/01/2010","start_date":" 01/01/2010","primary_txt":" Primary completion: 01/01/2013","primary_completion_date":" 01/01/2013","study_txt":" Completion: 02/01/2013","study_completion_date":" 02/01/2013","last_update_posted":"2020-06-11"},{"id":"ced3ddfc-aecc-483f-b6ba-df1ba61c1bcc","acronym":"","url":"https://clinicaltrials.gov/study/NCT01999738","created_at":"2021-01-18T09:07:36.380Z","updated_at":"2024-07-02T16:37:03.004Z","phase":"Phase 1","brief_title":"Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT01999738","lead_sponsor":"Endocyte","biomarkers":" EGFR • PD-L1 • ALK • BRCA1 • BRCA2 • ROS1 • BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["EGFR • PD-L1 • ALK • BRCA1 • BRCA2 • ROS1 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e folate-tubulysin (EC1456)"],"overall_status":"Completed","enrollment":" Enrollment 93","initiation":"Initiation: 10/01/2013","start_date":" 10/01/2013","primary_txt":" Primary completion: 12/31/2017","primary_completion_date":" 12/31/2017","study_txt":" Completion: 04/26/2018","study_completion_date":" 04/26/2018","last_update_posted":"2019-02-07"}]